A clinical approach to inherited arrhythmias

Circulation: Cardiovascular Genetics

Volumn 5, Issue 5, 2012, Pages 581-590

  Cerrone, Marina ^a   Cummings, Samori ^a   Alansari, Tarek ^a   Priori, Silvia G ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IRCCS   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AJMALINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLECAINIDE; MEXILETINE; NADOLOL; PROCAINAMIDE; QUINIDINE;

AUTOSOMAL DOMINANT INHERITANCE; BRUGADA SYNDROME; CASQ2 GENE; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CHANNELOPATHY; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEART ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; KCNH2 GENE; KCNQ1 GENE; LONG QT SYNDROME; NONHUMAN; PENETRANCE; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RYR2 GENE; SCN5A GENE; SHORT QT SYNDROME; ST SEGMENT ELEVATION;

ADRENERGIC BETA-ANTAGONISTS; ARRHYTHMIAS, CARDIAC; BRUGADA SYNDROME; CHANNELOPATHIES; DEATH, SUDDEN, CARDIAC; HUMANS; KCNQ1 POTASSIUM CHANNEL; LONG QT SYNDROME; POTASSIUM CHANNELS, VOLTAGE-GATED; TACHYCARDIA, VENTRICULAR;

EID: 84868618814     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.110.959429     Document Type: Review

References (57)

1. Cerrone M, Priori SG. Genetics of sudden death: focus on inherited chan-nelopathies. Eur Heart J. 2011;32:2109-2118.
2. Goldenberg I, Moss AJ. Long QT syndrome. J Am Coll Cardiol. 2008;51:2291-2300. (Pubitemid 351783362)
3. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866-1874. (Pubitemid 36532312)
4. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292:1341-1344. (Pubitemid 39223225)
5. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103:89-95. (Pubitemid 32050441)
6. Zhang L, Timothy KW, Vincent GM, Lehmann MH, Fox J, Giuli LC, et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation. 2000;102:2849-2855.
7. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation. 1999;99:529-533. (Pubitemid 29061868)
8. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA. 2005;294:2975-2980. (Pubitemid 41817658)
9. Goldenberg I, Moss AJ, Bradley J, Polonsky S, Peterson DR, McNitt S, et al. Long-QT syndrome after age 40. Circulation. 2008;117:2192-2201.
10. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 2000;102:1178-1185.
11. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005;2:507-517. (Pubitemid 40521365)
12. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011;8:1308-1339.
13. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association task force and the European Society of Cardiology committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death). J Am Coll Cardiol. 2006;48:e247-e346. (Pubitemid 44382683)
14. Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantu F, Towbin JA, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995;92:3381-3386.
15. Moss AJ, Windle JR, Hall WJ, Zareba W, Robinson JL, McNitt S, et al. Safety and efficacy of fecainide in subjects with long QT-3 syndrome (deltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol. 2005;10:59-66. (Pubitemid 44933555)
16. Ruan Y, Denegri M, Liu N, Bachetti T, Seregni M, Morotti S, et al. Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3. Circulation Research. 106:1374-1383.
17. Ruan Y, Liu N, Bloise R, Napolitano C, Priori SG. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation. 2007;116:1137-1144. (Pubitemid 47360216)
18. Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation. 1998;97:457-460. (Pubitemid 28090217)
19. Amin AS, Meregalli PG, Bardai A, Wilde AA, Tan HL. Fever increases the risk for cardiac arrest in the Brugada syndrome. Ann Internal Med. 2008;149:216-218.
20. Ikeda T, Abe A, Yusu S, Nakamura K, Ishiguro H, Mera H, et al. The full stomach test as a novel diagnostic technique for identifying patients at risk of Brugada syndrome. J Cardiovasc Electrophysiol. 2006;17:602-607.
21. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005;111:659-670.
22. Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA, Brugada P. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101:510-515. (Pubitemid 30080865)
23. Brugada R, Brugada P, Brugada J. Electrocardiogram interpretation and class I blocker challenge in Brugada syndrome. J Electrocardiol. 2006;39:S115-118. (Pubitemid 44465953)
24. Probst V, Denjoy I, Meregalli PG, Amirault JC, Sacher F, Mansourati J, et al. Clinical aspects and prognosis of Brugada syndrome in children. Circulation. 2007;115:2042-2048. (Pubitemid 46625955)
25. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, et al. Natural history of Brugada syndrome: insights for risk stratifica-tion and management. Circulation. 2002;105:1342-1347. (Pubitemid 34260426)
26. Hermida JS, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol. 2004;43:1853-1860. (Pubitemid 38622526)
27. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004;110:1731-1737. (Pubitemid 39299213)
28. Gehi AK, Duong TD, Metz LD, Gomes JA, Mehta D. Risk stratifica-tion of individuals with the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol. 2006;17:577-583.
29. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada syndrome registry. Circulation. 2010;121:635-643.
30. Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation. 2002;105:73-78. (Pubitemid 34049145)
31. Priori S, Gasparini M, Napolitano C, Della Bella P, Ghidini Ottonelli A, Sassone B, et al. Risk stratification in Brugada syndrome. Results of the PRELUDE registry. J Am Coll Cardiol. 2012 Jan 3; 59(1):37-45.
32. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrilla-tion. Nature. 1998;392:293-296. (Pubitemid 28155103)
33. Burashnikov E, Pfeiffer R, Barajas-Martinez H, Delpon E, Hu D, Desai M, et al. Mutations in the cardiac L-type calcium channel associated with inherited j wave syndromes and sudden cardiac death. Heart Rhythm. 2010;7:1872-1882.
34. Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott JJ, et al. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest. 2008;118:2260-2268. (Pubitemid 351872343)
35. Hu D, Barajas-Martinez H, Burashnikov E, Springer M, Wu Y, Varro A, et al. A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet. 2009;2:270-278.
36. London B, Michalec M, Mehdi H, Zhu X, Kerchner L, Sanyal S, et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation. 2007;116:2260-2268. (Pubitemid 350100331)
37. Smits JP, Eckardt L, Probst V, Bezzina CR, Schott JJ, Remme CA, et al. Genotype-phenotype relationship in Brugada syndrome: Electro-cardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol. 2002;40:350-356. (Pubitemid 34756299)
38. Gussak I, Brugada P, Brugada J, Wright RS, Kopecky SL, Chaitman BR, Bjerregaard P. Idiopathic short QT interval: a new clinical syndrome? Cardiology. 2000;94:99-102. (Pubitemid 32110328)
39. Maury P, Extramiana F, Sbragia P, Giustetto C, Schimpf R, Duparc A, et al. Short QT syndrome. Update on a recent entity. Arch Cardiovasc Dis. 2008;101:779-786.
40. Giustetto C, Di Monte F, Wolpert C, Borggrefe M, Schimpf R, Sbragia P, et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J. 2006;27:2440-2447. (Pubitemid 44522151)
41. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation. 2004;109:30-35. (Pubitemid 38056017)
42. Bellocq C, Van Ginneken AC, Bezzina CR, Alders M, Escande D, Mannens MM, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation. 2004;109:2394-2397. (Pubitemid 38679556)
43. Priori SG, Pandit SV, Rivolta I, Berenfibro O, Ronchetti E, Dhamoon A, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res. 2005;96:800-807. (Pubitemid 40559520)
44. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103:196-200. (Pubitemid 32095402)
45. Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in bedouin families from Israel. Am J of H Gen. 2001;69:1378-1384. (Pubitemid 33124218)
46. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation. 1995;91:1512-1519.
47. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, et al. Clinical and molecular characterization of patients with catechol-aminergic polymorphic ventricular tachycardia. Circulation. 2002;106:69-74. (Pubitemid 34747444)
48. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119:2426-2434.
49. Cerrone M, Colombi B, Bloise R, Memmi M, Moncalvo C, Potenza D, et al. Clinical and molecular characterization of a large cohort of patients affected with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2004;110:552.
50. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nature Med. 2009;15:380-383.
51. Liu N, Denegri M, Ruan Y, Avelino-Cruz JE, Perissi A, Negri S, et al. Short communication: fecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. Circ Res. 2011;109:291-295.
52. Van Der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011;57:2244-2254.
53. Liu N, Colombi B, Memmi M, Zissimopoulos S, Rizzi N, Negri S, et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res. 2006;99:292-298. (Pubitemid 44174937)
54. Cerrone M, Noujaim SF, Tolkacheva EG, Talkachou A, O'Connell R, Berenfibro O, et al. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res. 2007;101:1039-1048. (Pubitemid 350084981)
55. Rong B, Napolitano C, Bloise R, Monteforte N, Priori S. Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing. Circ Arrhythm Electrophysiol. 2009;2:6-15.
56. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, Hofman N, Bikker H, Van Tintelen JP, et al. The RyR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catechol-aminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol. 2009;54:2065-2074.
57. Cerrone M, De Giuli L, Bloise R, Monteforte N, Napolitano C, Priori SG. Value of entire open reading frame screening of RyR2. Evidence from the Italian CPVT registry. Heart Rhythm. 2011;8:S462.